Emergent Health Corp. (OTC Pink: EMGE) is focused on the development and sale of products within the regenerative health industry. The company’s products are developed as ingestibles and topicals for use by the whole family. Emergent Health also operates a wholly-owned subsidiary, PharmaZu Corp., which is an e-commerce pet pharmacy and wellness company.
Shares of the regenerative health company are skyrocketing 333% through early trading on Wednesday, June 29, 2022. Over the past thirty days, Emergent Health has seen average daily volume of 477,756 shares. However, volume of 12.66 million shares or dollar volume of around $438,036, has already exchanged hands through early trading.
Emergent Health shares are surging after the company announced that it has signed a binding letter of intent (LOI) to acquire Fusion Specialty Pharmacy, a nationally accredited compounding pharmacy with licenses in 27 states. Fusion offers personalized services to their patients by working closely with their physicians to create a customized formulation for treatment.
The company is accredited by the Pharmacy Compounding Accreditation Board (PCAB), which ensures the company is an approved compounding pharmacy that uses only the best and highest quality ingredients.
During 2021, Fusion Specialty Pharmacy generated revenues of over $3.8 million, which was a 100% year-over-year increase from its 2020 results. The acquisition is subject to financing and execution of definitive agreements. If all conditions are met, the transaction is estimated to close during the third quarter of 2022.
James Zimbler, CEO of Emergent Health: “We’re very excited about the upcoming acquisition of Fusion Specialty Pharmacy. Fusion will allow us to greatly expand our on-line pet-med offerings through our subsidiary, PharmaZu, Inc. Fusion will also allow Emergent to fulfill orders in all states.”
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/
